Cargando…
Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells
[Image: see text] Janus kinase (JAK) deregulation of the JAK/signal transducers and activators of transcription pathway leads to myelofibrosis that can be treated by JAK inhibitors including Ruxolitinib and Tofacitinib. Even though both inhibitors are effective against myelofibrosis, each of them ha...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260937/ https://www.ncbi.nlm.nih.gov/pubmed/35811912 http://dx.doi.org/10.1021/acsomega.2c02404 |
_version_ | 1784742154121248768 |
---|---|
author | Siriwaseree, Jeeraprapa Sanachai, Kamonpan Aiebchun, Thitinan Tabtimmai, Lueacha Kuaprasert, Buabarn Choowongkomon, Kiattawee |
author_facet | Siriwaseree, Jeeraprapa Sanachai, Kamonpan Aiebchun, Thitinan Tabtimmai, Lueacha Kuaprasert, Buabarn Choowongkomon, Kiattawee |
author_sort | Siriwaseree, Jeeraprapa |
collection | PubMed |
description | [Image: see text] Janus kinase (JAK) deregulation of the JAK/signal transducers and activators of transcription pathway leads to myelofibrosis that can be treated by JAK inhibitors including Ruxolitinib and Tofacitinib. Even though both inhibitors are effective against myelofibrosis, each of them has a different mode of action in the cells. Ruxolitinib is an inhibitor for selective JAK1/2, and Tofacitinib is an inhibitor for JAK3. This study evaluated the chemical fingerprints of TF-1 cells after JAK inhibitor treatments by the synchrotron Fourier transform infrared microspectroscopy (S-FTIR) spectrum. Tofacitinib and Ruxolitinib treatments in TF-1 cells were applied with a chemical fingerprint approach in S-FTIR spectroscopy and in vitro cytotoxicity in a cell-based assay. Principal component analysis or PCA was utilized to classify three cell treatments with three biochemical alteration absorbances of lipid vibration by the C–H stretching, protein amide I that appeared from the C=O stretching, and a P=O phosphodiester bond from nucleic acids. The results showed that the inhibition effect of Ruxolitinib on the TF-1 cell lines was two-fold higher than Tofacitinib. PCA distinguishes untreated and drug-treated cells by detecting cellular biochemical alteration. The loading plots identify that proteins and nucleic acids were the different main components in disparate cell treatments. Tofacitinib was distinct from the others in lipid and nucleic acid. The second derivative spectra of the three molecular components had decreased lipid production and accumulation, changes in secondary structures in proteins, and a high level of RNA overexpression in cell treatment. The JAK inhibitors caused different spectroscopic biomarkers of the modifications of secondary protein conformation, stimulated cell lipid accumulation, and phosphorylation from untreated cells. The alteration of cellular biochemical components suggests that FTIR is a potential tool to analyze specific patterns of drug cellular responses at the molecular level. |
format | Online Article Text |
id | pubmed-9260937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-92609372022-07-08 Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells Siriwaseree, Jeeraprapa Sanachai, Kamonpan Aiebchun, Thitinan Tabtimmai, Lueacha Kuaprasert, Buabarn Choowongkomon, Kiattawee ACS Omega [Image: see text] Janus kinase (JAK) deregulation of the JAK/signal transducers and activators of transcription pathway leads to myelofibrosis that can be treated by JAK inhibitors including Ruxolitinib and Tofacitinib. Even though both inhibitors are effective against myelofibrosis, each of them has a different mode of action in the cells. Ruxolitinib is an inhibitor for selective JAK1/2, and Tofacitinib is an inhibitor for JAK3. This study evaluated the chemical fingerprints of TF-1 cells after JAK inhibitor treatments by the synchrotron Fourier transform infrared microspectroscopy (S-FTIR) spectrum. Tofacitinib and Ruxolitinib treatments in TF-1 cells were applied with a chemical fingerprint approach in S-FTIR spectroscopy and in vitro cytotoxicity in a cell-based assay. Principal component analysis or PCA was utilized to classify three cell treatments with three biochemical alteration absorbances of lipid vibration by the C–H stretching, protein amide I that appeared from the C=O stretching, and a P=O phosphodiester bond from nucleic acids. The results showed that the inhibition effect of Ruxolitinib on the TF-1 cell lines was two-fold higher than Tofacitinib. PCA distinguishes untreated and drug-treated cells by detecting cellular biochemical alteration. The loading plots identify that proteins and nucleic acids were the different main components in disparate cell treatments. Tofacitinib was distinct from the others in lipid and nucleic acid. The second derivative spectra of the three molecular components had decreased lipid production and accumulation, changes in secondary structures in proteins, and a high level of RNA overexpression in cell treatment. The JAK inhibitors caused different spectroscopic biomarkers of the modifications of secondary protein conformation, stimulated cell lipid accumulation, and phosphorylation from untreated cells. The alteration of cellular biochemical components suggests that FTIR is a potential tool to analyze specific patterns of drug cellular responses at the molecular level. American Chemical Society 2022-06-23 /pmc/articles/PMC9260937/ /pubmed/35811912 http://dx.doi.org/10.1021/acsomega.2c02404 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Siriwaseree, Jeeraprapa Sanachai, Kamonpan Aiebchun, Thitinan Tabtimmai, Lueacha Kuaprasert, Buabarn Choowongkomon, Kiattawee Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells |
title | Synchrotron Fourier Transform Infrared Microscopy
Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis
Cancer Cells |
title_full | Synchrotron Fourier Transform Infrared Microscopy
Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis
Cancer Cells |
title_fullStr | Synchrotron Fourier Transform Infrared Microscopy
Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis
Cancer Cells |
title_full_unstemmed | Synchrotron Fourier Transform Infrared Microscopy
Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis
Cancer Cells |
title_short | Synchrotron Fourier Transform Infrared Microscopy
Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis
Cancer Cells |
title_sort | synchrotron fourier transform infrared microscopy
spectra in cellular effects of janus kinase inhibitors on myelofibrosis
cancer cells |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260937/ https://www.ncbi.nlm.nih.gov/pubmed/35811912 http://dx.doi.org/10.1021/acsomega.2c02404 |
work_keys_str_mv | AT siriwasereejeeraprapa synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells AT sanachaikamonpan synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells AT aiebchunthitinan synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells AT tabtimmailueacha synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells AT kuaprasertbuabarn synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells AT choowongkomonkiattawee synchrotronfouriertransforminfraredmicroscopyspectraincellulareffectsofjanuskinaseinhibitorsonmyelofibrosiscancercells |